Although in-vivo measures of amyloid-β (Aβ) and tau pathology in the brain and cerebrospinal fluid (CSF) have substantially improved the accuracy of AD diagnosis and prognosis [2–4], they remain costly and invasive, making them largely inaccessible to primary clinical care settings [5]. Here, MAPT is linked to Alzheimer disease.